SUBSCRIBE
SUBSCRIBE
News   Policy

FDA to Review Arcoxia, Merck & Co., Inc.'s (Jobs) Follow-Up to Vioxx

March 5, 2007 | 
1 min read
A Food and Drug Administration panel in April will review Merck's Arcoxia, its follow-up to the controversial painkiller Vioxx, which was pulled from the market in 2004 following safety concerns.

>>> Discuss This Story

Regulatory
Merck & Co. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
Regulatory
FDA Frictions Continue as White House Denies Promotion to Makary’s Aide
November 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Vector Illustration Of Athletes Running On Race Track
Regulatory
6 Biotechs With a Shot at the FDA’s Platform Technology Designation
November 21, 2025
 · 
9 min read
 · 
Tristan Manalac
Four miniature figurines of men in casual and formal attire stand around a large stopwatch showing zero, symbolizing time management or competition.
Regulatory
FDA Breakthrough Designations Lead to Priority Reviews, Report Finds
November 20, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Bayer office in Basel, Switzerland
Lung cancer
Bayer Wins Lung Cancer Accelerated Approval for Kinase Inhibitor
November 20, 2025
 · 
1 min read
 · 
Tristan Manalac